ICON Public Company (ICLR) Jefferies London Healthcare Conference 2024 summary

Recent performance and outlook

• Q3 was disappointing due to late, significant impacts from top two customers, leading to reduced guidance, which is reiterated for 2024.

• 50 quarters of solid earnings and revenue progression, with Q3 seen as an anomaly; recovery expected within a couple of quarters.

• Targeting low to mid-single-digit revenue growth in 2025, with firm guidance to be provided at the J.P. Morgan Conference in January.

• Growth outside the top two customers is mid-single digits or higher, indicating portfolio strength.

• Industry outlook remains solid mid- to long-term, with near-term challenges expected over the next two to three quarters.

Customer and market dynamics

• Strategic partnerships now include 17 of the top 20 pharma companies, with three new partners added in the last year.

• Large pharma expected to grow at 3%-5% annually, with volatility in vaccine and some therapeutic areas.

• One top customer is projected to continue declining in 2025, but this is factored into forecasts; another is rebounding.

• Vaccine business is therapeutically strong but currently low single digits due to cancellations and delays, expected to recover to mid-single digits next year.

• Biotech market remains volatile with slow decision cycles, but RFP activity is improving and high single-digit growth is anticipated by 2026.

Operational initiatives and efficiency

• Centralization of key functions and automation initiatives are driving margin improvement and operational efficiency.

• Automation is on track, with 3.5 million hours expected this year, translating to $70-$75 million in cost savings.

• Automation and centralization are critical for scaling and improving processes across data management, medical writing, and RFP handling.

• 20%-30% of RFP dollars do not result in decisions, reflecting some inefficiency in the current market environment.